Cathepsin B

Cathepsin B

Cathepsin B Overview

Molecule Name
Cathepsin B
Synonyms
CTSB,CPSB,APPS
Drug Development Progress
Drugs in Clinical Trials2
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
EC 3.4.22,EC:3.4.22.1,RECEUP,Cathepsin B,Amyloid Precursor Protein Secretase,Epididymis Secretory Sperm Binding Protein,Cathepsin B1,Cysteine Protease,EC 3.4.22.1,CPSB,APPS,APP secretase,CTSB
Background
Cathepsin B (CTSB) is also known as APP secretase (APPS) and CPSB, is an enzymatic protein belonging to the peptidase C1 family. Cathepsin B / CTSB is synthesized as a preproenzyme. Following removal of the signal peptide, the inactive proenzyme undergoes further modifications including removal of the pro region to result in the active enzyme. The catalytic activity of Cathepsin B / APPS contains: Hydrolysis of proteins with broad specificity for peptide bonds; Preferentially cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates (thus differing from cathepsin L); In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. As a thiol protease, cathepsin B / CPSB is believed to participate in intracellular degradation and turnover of proteins and has also been implicated in tumor invasion and metastasis. Overexpression of cathepsin B has been associated with esophageal adenocarcinoma and other tumors.

Cathepsin B Product List

Species
  • Human(3)
  • Mouse(1)
Tag
  • His Tag(3)
  • Tag Free(1)
Host
  • HEK293(4)
Conjugate
  • Unconjugated(4)
Grade
  • RUO(4)
Low Endotoxin
  • No(4)
You Have Viewed 1-4 Of 4 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
OsugacestatAL-101(BMS); BMS-906024; BM-0018Phase 2 ClinicalBristol-Myers Squibb Company, Glaxosmithkline Plc
Carcinoma, Adenoid Cystic; Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Triple Negative Breast Neoplasms
Details
cysteine protease inhibitor (Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim International Gmbh
Respiratory Tract Diseases
Details
Customer Reviews
  • M***i2025-04-05
    Product was purchased to utilize in a val-cit cleavage assay for a protein-drug conjugate. The protein did not take long to arrive and the assay instructions were clear to follow and promptly given upon request. I was readily able to utilize the protein for the desired cleavage assay using the provided protocol and it worked great. I am satisified with the quality and the price of this reagent.